scholarly journals Nicotine patch vs. nicotine lozenge for smoking cessation: An effectiveness trial coordinated by the Community Clinical Oncology Program

2010 ◽  
Vol 107 (2-3) ◽  
pp. 237-243 ◽  
Author(s):  
Robert A. Schnoll ◽  
Elisa Martinez ◽  
Kristina L. Tatum ◽  
Marcella Glass ◽  
Albert Bernath ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Clinical Oncology ◽  
Nicotine Patch ◽  
Effectiveness Trial ◽  
Community Clinical Oncology Program ◽  
Nicotine Lozenge

scholarly journals New Biomarkers Based on Smoking-Related Phenotypes for Smoking Cessation Outcomes of Nicotine Replacement Therapy: A Prospective Study

2021 ◽  
Author(s):  
Arash Nikkholgh ◽  
◽  
Soltan Ahmad Ebrahimi ◽  
Enayatollah Bakhshi ◽  
Mohammad-Reza Zarrindast ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Treatment Outcomes ◽  
Nicotine Patch ◽  
Binary Logistic Regression ◽  
Nicotine Replacement ◽  
Logistic Regression Models ◽  
Nicotine Lozenge ◽  
New Biomarkers ◽  
A Prospective Study

Introduction: Identification of a potent biomarker related to smoking cessation can play a key role in predicting prognosis and improving treatment outcomes. This study aimed to evaluate the contribution of new biomarkers based on levels of cotinine (Cot) and/or carbon monoxide (CO) to the short- and long-term quit rates of nicotine replacement therapies (nicotine patch (NP) and nicotine lozenge (NL)). Methods: In this prospective interventional study, a sample of 124 smokers under treatment with the 5A's method was selected between April 2016 and December 2018 in an outpatient smoking cessation center in 18th region of Tehran. They were divided into two groups for NP (n = 56) and NL (n = 61) interventions. The levels of Cot and CO were measured using ELISA and breath analysis at the beginning of the study. Three markers were calculated: Cot/CO, Cot to cigarette per day ratio (Cot/CPD), and CO/CPD. To determine the odds of smoking cessation success, binary logistic regression models and generalized estimating equations (GEE) model were analyzed by SPSS software. Results: Of the NP participants, 30.4% and 19.6% were abstinent in 2 and 6 months respectively, while NL was found less effective with 19.7% for 2-month follow-up and 13.1% for 6-month follow-up. The 6-month success of attempts to quit was significantly different for the NP participants at the second half of Cot/CO (P = 0.029). In the NL participants, CO/CPD would be a superior predictor for the success of smoking cessation (P > 0.05). Conclusions: The findings of this study suggested two markers, Cot/CO and CO/CPD in order, for the optimum treatment outcomes of NP and NL.

The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia

2004 ◽  
Vol 41 (3) ◽  
pp. 321-330 ◽  
Author(s):  
Kuei-Ru Chou ◽  
Ruey Chen ◽  
Jia-Fu Lee ◽  
Chih-Hung Ku ◽  
Ru-Band Lu
Keyword(s):  
Smoking Cessation ◽  
Nicotine Patch

scholarly journals Study Characteristics Influence the Efficacy of Substance Abuse Treatments: A Meta-analysis of Medications for Smoking Cessation

2018 ◽  
Vol 22 (3) ◽  
pp. 317-323 ◽  
Author(s):  
Elias M Klemperer ◽  
John R Hughes ◽  
Shelly Naud
Keyword(s):  
Smoking Cessation ◽  
Treatment Efficacy ◽  
Linear Models ◽  
Nicotine Patch ◽  
Meta Analysis ◽  
Individual Characteristics ◽  
Odds Ratios ◽  
Industry Funding ◽  
Cochrane Reviews ◽  
Study Characteristics

Abstract Background Understanding study characteristics’ influence on treatment efficacy could improve interpretation of trials’ outcomes. We examined study characteristics as predictors of outcomes in clinical trials of medications for tobacco use. Methods We obtained and analyzed data on 44 trials of nicotine gum, 37 trials of nicotine patch, 27 trials of varenicline, and 43 trials of bupropion from Cochrane reviews. We extracted and analyzed data for 15 study characteristics, odds ratios (ORs), and percent abstinent in control and medication conditions. We used general linear models to determine which study characteristics explained the variability among outcomes after controlling for medication characteristics. Results Study characteristics accounted for 12% of the variance in odds ratios among patch trials, 16% among gum trials, 16% among varenicline trials, and 34% among bupropion trials above and beyond medication characteristics. Patch and gum trials with industry funding had larger odds ratios than those without. Among patch trials, this appeared to be due to less abstinence in industry-funded trials’ control conditions. Bupropion trials published earlier had larger odds ratios, which appeared to be due to less abstinence in control conditions. The reason for study characteristics’ influence on varenicline trials was unclear. Discussion Study characteristics influenced the assessment of treatment efficacy above and beyond medication characteristics in smoking cessation trials. Our findings that study characteristics are associated with higher or lower efficacy does not suggest that the effect size under one versus another condition is the more valid outcome. Future studies are needed to determine which study characteristics reliably influence efficacy because this would help investigators and clinicians interpret trials. Implications Study characteristics influenced the estimates of treatment efficacy but individual characteristics’ influence on efficacy appeared to differ among different medications for smoking cessation. We encourage researchers to report study characteristics to improve interpretation of findings and systematic reviews, and to account for nontreatment-related variables to better estimate the efficacy of treatments.

Combination Rapid-Acting Nicotine Mouth Spray and Nicotine Patch Therapy in Smoking Cessation

2014 ◽  
Vol 16 (10) ◽  
pp. 1356-1364 ◽  
Author(s):  
Brent O. Caldwell ◽  
Simon J. Adamson ◽  
Julian Crane
Keyword(s):  
Smoking Cessation ◽  
Nicotine Patch
Sign in / Sign up

Export Citation Format

Share Document